Retatrutide vs. Semaglutide 2 mg: TRANSCEND-T2D-2 Results and Limits
Study and evidence status
Lilly reports greater glucose and weight reductions with retatrutide, alongside more adverse-event discontinuations. These are sponsor topline findings; peer-reviewed details are pending. Retatrutide remains investigational and not FDA-approved.[1]
The registry confirms a randomized, open-label Phase 3 comparison in adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. HbA1c change at 80 weeks is the primary outcome; weight change is secondary.[2]
Enrollment source distinction: Lilly reports 1,298 participants.[1] The registry record, last posted September 28, still lists 1,250 as an estimate and has no posted results. It verifies the study design, not the announcement's numerical findings.[2]
Efficacy and safety
| Outcome | Retatrutide 9 mg | Retatrutide 12 mg | Semaglutide 2 mg |
|---|---|---|---|
| HbA1c change (percentage points) | −2.2 | −2.2 | −1.8 |
| Weight reduction (%) | 19.5 | 20.9 | 9.4 |
| Adverse-event discontinuation (%) | 4.8 | 7.9 | 2.7 |
| Dysesthesia (%) | 4.8 | 6.5 | 2.7 |
| Diarrhea (%) | 28.3 | 32.7 | 26.4 |
| Nausea (%) | 21.2 | 23.8 | 21.3 |
| Vomiting (%) | 10.2 | 15.0 | 13.2 |
The efficacy estimand assumes continued assigned treatment, allowing interruptions/modifications, without additional glucose-lowering medication for more than 14 days. The 9 mg HbA1c superiority result is nominal; 12 mg HbA1c superiority and both weight comparisons controlled multiplicity (p<0.001).[1]
How to interpret the comparison
The comparator is injectable semaglutide 2 mg (Ozempic). This trial cannot establish superiority over other semaglutide doses, tirzepatide, or treatment in people without diabetes. Direct randomization makes this comparison more informative than ranking percentages from unrelated trials.
An efficacy estimand answers a hypothetical adherence question. It should not be presented as the average result everyone starting treatment will experience. Open-label treatment also makes expectations and behavior possible influences; randomization does not remove every source of bias.
Higher discontinuation and dysesthesia rates deserve attention alongside weight loss. These descriptive percentages do not establish statistical differences for every adverse event. A fuller assessment needs confidence intervals, missing-data methods, treatment-regimen results, and complete serious-adverse-event reporting. Unreported safety details must not be read as zero events.
Retatrutide evidence profile · The separate HHS six-peptide policy does not include retatrutide.